Actively Recruiting
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Led by Roberto Vargas · Updated on 2026-03-19
4
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.
CONDITIONS
Official Title
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically proven metastatic cancer (including carcinoma, adenocarcinoma, sarcoma, or neuroendocrine cancer)
- Metastatic disease confirmed by imaging, typically CT scan of the chest/abdomen/pelvis
- Measurable disease according to RECIST 1.1
- Age over 18 years
- ECOG performance status of 0 or 1
- Adequate organ function based on recent lab tests including liver enzymes, bilirubin, blood counts, calcium, and creatinine levels
- Ability to understand and willingness to sign informed consent
- Ability to remain still during imaging (up to one hour)
You will not qualify if you...
- History within 6 months of myocardial infarction, severe or unstable angina, severe peripheral vascular disease, vascular procedures, coronary or peripheral artery bypass graft, heart failure grade II or greater, stroke, transient ischemic attack, significant bleeding, or pulmonary embolism
- Pregnant or breastfeeding women
- Other severe acute or chronic medical or psychiatric conditions or lab abnormalities that increase risk or interfere with study participation or results according to investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
Research Team
R
Roberto Vargas, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here